RxSight, Inc. RXST · NASDAQ
$4.54 +0.00% (+$0.00)
Summary
58 / 100 · Bulios Score
What speaks for it
- Revenue grew by 40% a year over the last 3 years.
- It holds more cash than debt: $66.7M against $10.3M.
- Out of every 100 USD of revenue, 15 USD is left as free cash.
What to watch
- The company made a loss over the last 12 months.
- The share price is above the Bulios Fair Price.
- It passes only 2 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 56% a year over 5 years. Over the last 3 years it grew by 40% a year. For the next fiscal year analysts expect revenue to grow by 9.8%.
Growth in detailDoes it make money?
ReasonablyOver the last 12 months it made a loss of $53.4M.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 3
- Hold 7
- Sell 2
Today's price within the analysts' price targets
The average target of $7.05 is 55% above today's price. 25% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- RxLAL 80%
- L D D 15%
- Service Warranty Service Contracts And Accessories 4.3%
By region
The company reports no revenue by region.
RxLAL brings in 80% of revenue. Service Warranty Service Contracts And Accessories grew fastest, by 72% a year.
Segments in detail